Direct-Acting Antiviral Agents: Regimens for the Interferon Failure Patient.

Over the past few years, tremendous advances have been made in the treatment of hepatitis C with direct-acting antiviral agents (DAAs), allowing treatment options for patients who have failed prior treatment with interferon. In addition to interferon's severe adverse effect profile, and the inability of many patients to tolerate it, prior interferon-containing regimens were not as effective in achieving sustained virologic response as emerging therapies. New DAAs have demonstrated higher rates of sustained virologic response, shorter duration of treatment, and improved adverse effect profile.